Skip to main content
European Commission logo print header

Faron leading the way in macrophage guided immunotherapy

Descrizione del progetto

Un trattamento innovativo che rompe la tolleranza immunitaria nel cancro

Il cancro ha un impatto devastante su milioni di persone in tutto il mondo, eppure non è stato sviluppato alcun trattamento efficace contro di esso. Il progetto MAGIF, finanziato dall’UE, sta lavorando ad una nuova soluzione antitumorale basata sulla molecola immunosoppressiva chiave Clever-1 che si trova sui macrofagi associati al tumore. Un anticorpo contro la Clever-1 scavalca la tolleranza immunitaria dei tumori e attiva la difesa immunitaria del paziente contro il cancro. I risultati preliminari delle sperimentazioni cliniche sull’uomo sono molto incoraggianti e dimostrano la stimolazione immunitaria e la riduzione del tumore. Il progetto MAGIF si concentrerà sui tipi di cancro privi di opzioni terapeutiche efficaci, nella speranza di aprire la strada all’immunoterapia guidata da macrofagi.

Obiettivo

Cancer is a leading cause of death in the world despite relentless research to discover new treatments. There were over 18M new cancer cases and 9.6M deaths due to cancer worldwide in 2018. Human suffering due to cancer is devastating. The impact and cost of cancer to society is extensive and complex. Faron aims to provide a new solution that could replace several currently used ineffective cancer treatments.
Faron is a Finnish biotech company committed to high-quality R&D to fulfil the company’s mission of saving lives. Faron’s game-changing immuno-oncology (IO) treatment CLEVEGEN revolves around a key immunosuppressive molecule named Clever-1 on tumour associated macrophages, responsible for cancer growth and spread. CLEVEGEN is an anti-Clever-1 antibody that brakes the immunosuppressive tolerance of tumours and activates the patient’s immune defences against cancer.
The first results from Faron’s first-in-human clinical trial with CLEVEGEN are very positive with early clinical benefits with a switch in patients’ immune profile towards immune stimulation leading to tumour shrinkage in cancer types where nothing has worked before. The early evidence of a clinical response to CLEVEGEN strengthens Faron’s value proposition of it as a break-through cancer treatment.
CLEVEGEN has major advantages compared to other IO treatments. Most importantly, patients who would benefit from the treatment can be screened. This would prevent futile treatment and deliver savings in healthcare resources and cost. The CLEVEGEN program is focused on deadly cancer types without effective treatment options and over 3.5M new cases and 2.3M deaths yearly. The market opportunity is clear. With transition to other cancers and the possibility of becoming the first line of therapy due to an exceptional safety profile, the potential up-scale of CLEVEGEN is enormous.
There is nothing like CLEVEGEN on the market. CLEVEGEN could secure Faron a world-leading position in the new wave of macrophage guided immunotherapy.

Invito a presentare proposte

H2020-EIC-SMEInst-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-EIC-SMEInst-2018-2020-3

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Coordinatore

FARON PHARMACEUTICALS OY
Contribution nette de l'UE
€ 2 500 000,00
Indirizzo
JOUKAHAISENKATU 6
20520 Turku
Finlandia

Mostra sulla mappa

PMI

L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.

Regione
Manner-Suomi Etelä-Suomi Varsinais-Suomi
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 4 544 008,50